Vivos Therapeutics, Inc. (VVOS) Targets $3.6M Annual Cost Cuts, Eyes Cash-Flow Positive
Vivos Therapeutics announced a restructuring to cut about $3.6M annually starting Q4 2026 and outlined growth initiatives, including rising referrals, EEG testing run rate of $1.5—$3.0M in Q4, RPM up to $3.5M annualized by Q1 2027, and payer renegotiations of $2.4—$5.6M.Material DetailsContext by A…